Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T04079
(Former ID: TTDI01187)
|
|||||
| Target Name |
Plasmodial phospholipid metabolism (PPP metab)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Malaria [ICD-11: 1F40-1F45] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | SAR97276 | Drug Info | Phase 2 | Malaria | [2] | |
| 2 | CDRI-97/78 | Drug Info | Phase 1 | Malaria | [3] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | SAR97276 | Drug Info | [1] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | CDRI-97/78 | Drug Info | [4] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276. | |||||
| REF 2 | ClinicalTrials.gov (NCT00739206) Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.. U.S. National Institutes of Health. | |||||
| REF 3 | Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. MalarJ. 2015 Apr 22;14:172. | |||||
| REF 4 | Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.